Company Snapshot: KemPharm, Inc.
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. Its product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder. The company also provides APADAZ, an immediate-release combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. It has a collaboration agreement with KVK-Tech, Inc. to manufacture and commercialize APADAZ. The company was founded in 2006 and is headquartered in Celebration, Florida.
- Jan 24 2023 KemPharm Issues Letter to Shareholders
- Jan 18 2023 KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy
- Jan 11 2023 KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer
- Jan 9 2023 KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company